A. Guminski, N. Squittieri, and J. T. Lear, “Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study”, J of Skin, vol. 4, no. 5, p. s67, Sep. 2020.